Back

LIBerate-HeFH - a novel PCSK9-inhibitor in heterozygous FH

28 August 2023 (14:30 - 14:45)
Organised by: Logo
Congress Presentation Part of: Late-breaking science on pharmacology Drug therapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Frederick Raal

University of the Witwatersrand, Johannesburg (South Africa)

3 More presentations in this session

Presentation thumbnail
ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients
Professor R. Wright (Rochester, US)
Slides Video
Presentation thumbnail
Muvalaplin, a Potent Small Molecule Inhibitor of Lipoprotein(a)
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
REMAIN-1: A phase 3 study of recaticimab monotherapy in dyslipidaemia
Professor J. Ge (Shanghai, CN)
Slides Video

Access the full session

Session thumbnail
Late-breaking science on pharmacology
Video

The Event

Event poster

ESC Congress 2023

28 August 2023 14:30 CET
You may be interested in
thumbnail
Congress Presentation
New therapies to lower LDL-C: how to choose?
25 August 2023
thumbnail
Congress Presentation
Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins
28 August 2023
thumbnail
Congress Presentation
Efficacy and safety of pemafibrate in patients with statin-intolerant hypercholesterolemia: results from a 12-week, randomized, double blind, placebo-controlled, phase 3 trial
31 August 2025
thumbnail
Congress Presentation
Functional Improvement of non-infarcT relaTed coronary artery stenosis by Extensive LDL-C Reduction with a PCSK9 Antibody
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources